Výsledky vyhledávání - "Maja, Hojnik"

Akademický článek

Impact of adalimumab on clinical outcomes, healthcare resource utilization, and sick leave in patients with ankylosing spondylitis: an observational study from five Central and Eastern European countries

Autor: Daniela Opris-Belinski, Shandor F Erdes, Simeon Grazio, Ladislav Šenolt, Maja Hojnik, Orsolya Nagy, Diana Marina, Sándor Szántó

Publikováno v: Drugs in Context, Vol 7, Pp 1-8 (2018)

Background: Patients with ankylosing spondylitis (AS) are substantial users of healthcare resources due to chronic and potentially disabling disease. This study assessed the impact of adalimumab on clinical outcomes, healthcare resource utilizati

Externí odkaz: https://doaj.org/article/e2396b3fb73f471ca2beef980b90c20f

Zobrazit plný text záznamu

Akademický článek

Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial

Autor: Désirée van der Heijde, Joachim Sieper, Walter P. Maksymowych, Robert G. Lambert, Su Chen, Maja Hojnik, Jaclyn K. Anderson, Aileen L. Pangan

Publikováno v: Arthritis Research & Therapy, Vol 20, Iss 1, Pp 1-13 (2018)

Abstract Background Adalimumab was effective in treating patients with nonradiographic axial spondyloarthritis (nr-axSpA) in the 12-week ABILITY-1 trial. We present long-term efficacy and safety results of adalimumab from the open-label ABILITY-1 ext

Externí odkaz: https://doaj.org/article/38a09d984ba445db80056c5594275dae

Zobrazit plný text záznamu

Effects of ixekizumab treatment on structural changes in the sacroiliac joint

Autor: Walter P Maksymowych, Xenofon Baraliakos, Robert G Lambert, Robert Landewé, David Sandoval, Hilde Carlier, Jeffrey Lisse, Xiaoqi Li, Maja Hojnik, Mikkel Østergaard

Publikováno v: The Lancet Rheumatology, 4(9), e626-e634. Lancet Publishing Group

Background: There is limited understanding regarding the inhibition of structural damage in the sacroiliac joint of patients with non-radiographic axial spondyloarthritis. This study evaluated the effect of the interleukin-17A inhibitor ixekizumab ve

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ded7d1d7137bf9f1a21fbd3987e0e86
http://www.scopus.com/inward/record.url?scp=85136512630&partnerID=8YFLogxK

Zobrazit plný text záznamu

Akademický článek

Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study

Autor: Joachim Sieper, Josef S Smolen, Dafna Gladman, H Patrick McNeil, Maja Hojnik, Pascal Nurwakagari, John Weinman

Publikováno v: RMD Open, Vol 5, Iss 1 (2019)

Objective This analysis explored the association of treatment adherence with beliefs about medication, patient demographic and disease characteristics and medication types in rheumatoid arthritis (RA), psoriatic arthritis (PsA) or ankylosing spondyli

Externí odkaz: https://doaj.org/article/e1f97073fc5d4677b6fc1e4985940bf0

Zobrazit plný text záznamu

Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double‐Blind Withdrawal Study

Autor: Laura C, Coates, Sreekumar G, Pillai, Hasan, Tahir, Ivo, Valter, Vinod, Chandran, Hideto, Kameda, Masato, Okada, Lisa, Kerr, Denise, Alves, So Young, Park, David H, Adams, Gaia, Gallo, Matthew M, Hufford, Maja, Hojnik, Philip J, Mease, Arthur, Kavanaugh, Hana, Zelenkova

Publikováno v: Arthritis & Rheumatology (Hoboken, N.j.)

Objective To evaluate the effect of withdrawing ixekizumab in patients with psoriatic arthritis (PsA) in whom minimal disease activity (MDA) has been achieved after open-label ixekizumab treatment. Methods SPIRIT-P3 was a multicenter, randomized, dou

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ae56f2b60b94c6636f76133331dfedd
https://doi.org/10.1002/art.41716

Zobrazit plný text záznamu

Characteristics of patients with axial spondyloarthritis by geographic regions: PROOF multicountry observational study baseline results

Autor: Denis Poddubnyy, Joachim Sieper, Servet Akar, Santiago Muñoz-Fernández, Hildrun Haibel, Maja Hojnik, Fabiana Ganz, Robert D Inman

Publikováno v: ABACUS. Repositorio de Producción Científica
Universidad Europea (UEM)

Objectives To compare demographic and clinical characteristics of patients with axial SpA (axSpA) across geographic regions. Methods Patients With Axial Spondyloarthritis: Multicountry Registry of Clinical Characteristics (PROOF) is an observational

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74517b3a99280644a9d9355a675e01f6
https://pubmed.ncbi.nlm.nih.gov/34897381

Zobrazit plný text záznamu

Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity

Autor: Maja Hojnik, Robert Landewé, Fabiana Ganz, Daniel Aletaha, Ying Zhang, Christopher T. Ritchlin, Laura C. Coates

Publikováno v: Rheumatology (Oxford, England), 58(6), 1025-1033. Oxford University Press
Rheumatology (Oxford, England)

Objectives To evaluate the relationship between radiographic progression and disease activity in subjects with PsA treated with adalimumab (ADA) or placebo (PBO) and the impact of concomitant MTX. Methods This was a post hoc analysis of the randomize

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50365b2f004d03a0e9e2d8ca4a9c3602
https://doi.org/10.1093/rheumatology/key417

Zobrazit plný text záznamu

Low Incidence of Inflammatory Bowel Disease Adverse Events in Adalimumab Clinical Trials Across Nine Different Diseases

Autor: Maja Hojnik, Jürgen Braun, Jaclyn Anderson, Su Chen, Ann-Sophie De Craemer, Jeffrey R. Curtis, Dilek Arikan, Dirk Elewaut

Publikováno v: Arthritis Care & Research
ARTHRITIS CARE & RESEARCH

OBJECTIVE Adalimumab is approved for treatment of Crohn's disease and ulcerative colitis. Thus, we postulated that exacerbation or new-onset of inflammatory bowel disease (IBD) would be rare events in patients treated with adalimumab for non-IBD indi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59f0e603fc8842604bf69602e4530270
https://pubmed.ncbi.nlm.nih.gov/32100944

Zobrazit plný text záznamu

Autor: Orsolya Nagy, Simeon Grazio, Shandor F Erdes, Sándor Szántó, Ladislav Šenolt, Maja Hojnik, Diana Marina, Daniela Opris-Belinski

Publikováno v: Drugs in Context
Drugs in Context, Vol 7, Pp 1-8 (2018)

Background Patients with ankylosing spondylitis (AS) are substantial users of healthcare resources due to chronic and potentially disabling disease. This study assessed the impact of adalimumab on clinical outcomes, healthcare resource utilization, a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0816dd0005f4c5269a3521425e7fb0dc
https://pubmed.ncbi.nlm.nih.gov/30483351

Zobrazit plný text záznamu

Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial

Autor: Maja Hojnik, Walter P. Maksymowych, Joachim Sieper, Su Chen, Désirée van der Heijde, Jaclyn K Anderson, Robert G. Lambert, Aileen L. Pangan

Publikováno v: Arthritis Research & Therapy
Arthritis Research & Therapy, Vol 20, Iss 1, Pp 1-13 (2018)
Arthritis Research and Therapy, 20

Background Adalimumab was effective in treating patients with nonradiographic axial spondyloarthritis (nr-axSpA) in the 12-week ABILITY-1 trial. We present long-term efficacy and safety results of adalimumab from the open-label ABILITY-1 extension, i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99f591a90c7eb207fc104ddc1a79b7d5
https://doi.org/10.1186/s13075-018-1556-5

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání